Status:

COMPLETED

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Lead Sponsor:

AstraZeneca

Conditions:

Type 2 Diabetes Mellitus

Eligibility:

All Genders

18-130 years

Phase:

PHASE3

Brief Summary

This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite e...

Eligibility Criteria

Inclusion

  • Patient has type 2 diabetes mellitus
  • Patient has an HbA1c of ≥ 6.5 % and ≤ 10.0% and is currently using one of the following treatment regimens: A) Treatment with 0-3 oral antihyperglycemic agents B) Insulin therapy, either alone or in combination with up to two oral agents
  • Female patients must not be breast feeding and agree to use an effective method of contraception or must not otherwise be at risk of becoming pregnant.

Exclusion

  • Patient has a diagnosis of type 1 diabetes mellitus, or a history of ketoacidosis.
  • Patient has ever been treated with an approved or investigational GLP-1 receptor agonist.
  • Patient is enrolled in another experimental protocol which involves the use of an investigational drug or device, or an intervention that would interfere with the conduct of the trial.
  • Patient has a planned or anticipated revascularization procedure.
  • Pregnancy or planned pregnancy during the trial period.
  • Patient has end-stage renal disease or an estimated glomerular filtration rate (eGFR) of \<30 mL/min/1.73m2.
  • Patient has a history of gastroparesis or pancreatitis.
  • Personal or family history of medullary thyroid cancer or MEN2 (Multiple EndocrineNeoplasia Type 2) or calcitonin level of \>40 ng/L at baseline.

Key Trial Info

Start Date :

June 18 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 24 2017

Estimated Enrollment :

14752 Patients enrolled

Trial Details

Trial ID

NCT01144338

Start Date

June 18 2010

End Date

April 24 2017

Last Update

August 8 2018

Active Locations (629)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 158 (629 locations)

1

Research Site

Birmingham, Alabama, United States, 35294

2

Research Site

Glendale, Arizona, United States, 85306

3

Research Site

Phoenix, Arizona, United States, 85012

4

Research Site

Jonesboro, Arkansas, United States, 72401